RxDoctor Payments Data

Jacqueline Mereday

Physician Assistant · Albany, NYNPI 1285855841

Payments from drug & device makers

$3,370in general payments, 2019–2025

Across 156 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$630
  • Gilead$374
  • Ardelyx, Inc.$196
  • Intercept Pharmaceuticals, Inc.$186
  • Johnson & Johnson$150
  • plus $558 from 12 others

What the payments were for

  • Food & beverage$3,33699%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,370 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$22,546
Medicare patients
183
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide190$174,237
CreonLipase/Protease/Amylase19$60,030
XifaxanRifaximin15$42,330
MotegrityPrucalopride Succinate29$32,342
Mesalamine22$19,296
Omeprazole374$5,946
Lansoprazole29$5,467
Esomeprazole Magnesium63$5,065
Pantoprazole Sodium170$4,601
Famotidine294$4,340
Lubiprostone20$3,364
Sucralfate46$2,751
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine30$1,738
Dicyclomine Hcl39$1,578
Ondansetron OdtOndansetron45$1,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,276$234,268209 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$630$42,33015 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$116$32,34229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →